Management strategies for articular flares during biologic therapy in non-systemic polyarticular JIA: a multicentre study

Clicks: 17
ID: 329911
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #200 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Biologic disease-modifying antirheumatic drugs (bDMARDs) are the cornerstone of treatment for juvenile idiopathic arthritis (JIA), yet the optimal management of flares during ongoing biologic therapy remains unclear. We aimed to compare flare-management strategies and identify risk factors for treatment failure in non-systemic polyarticular JIA. METHODS: We conducted a multicentre retrospective cohort study across four tertiary paediatric centres in Israel (01/2008-12/2024). We included children with non-systemic polyarticular JIA phenotypes who achieved clinically inactive disease (CID) on a bDMARD and subsequently experienced an articular flare. Treatment success (TS) was defined as achieving CID within 3 months following intervention and maintaining it for ≥3 months. Multivariable logistic regression and Cox proportional hazards models were used to identify predictors of success and time to remission. RESULTS: Among 65 patients and 116 flares, five strategies were compared: NSAIDs alone (2.6%), intra-articular corticosteroid injection (IACI; 28.4%), biologic dose optimization (43.1%), IACI plus dose optimization (13.8%), and switching biologics (12.1%). Overall, 71.6% of flares achieved TS. Success rates were highest for IACI (81.8%) and dose optimization (76.0%), and lowest for biologic switching (35.7%). Multivariable analysis identified biologic switching as an independent predictor of lower CID achievement (adjusted OR 0.27; p = 0.036) and significantly delayed remission (HR 0.40; p = 0.006). CONCLUSIONS: In non-systemic polyarticular JIA, local and incremental strategies like IACI and dose optimization result in higher and faster remission rates compared to immediate biologic switching. A stepwise algorithm prioritizing treatment optimization may prevent unnecessary cycling of biologics.
Reference Key
openalex_W7214476329 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jonatan Zalcman, Yoel Levinsky, Dana Kenan, Adi Efron, Haran Shani-Narkiss, Irit Tirosh, Amit Ziv, Ruby Haviv, Yonatan Butbul Aviel, Ruth Livny, Gil Amarilyo
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag539
URL
https://doi.org/10.1093/rheumatology/keag539
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.